Question: Which grade under the Nottingham histologic grading system is supported by the tumor morphology?

Choices:
A. Grade 3
B. Grade 2
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 1


Question: What is the overall degree of histologic differentiation in this tumor?

Choices:
A. Undifferentiated or anaplastic
B. Well differentiated
C. Moderately differentiated
D. Poorly differentiated


Question: How should tumor differentiation appear in the final pathology assessment?

Choices:
A. Well differentiated
B. Moderately differentiated
C. Poorly differentiated
D. Undifferentiated or anaplastic


Question: How should tumor differentiation appear in the final pathology assessment?

Choices:
A. Poorly differentiated
B. Well differentiated
C. Moderately differentiated
D. Undifferentiated or anaplastic


Question: Using the FIGO histologic grading system, which grade should be assigned to this tumor?

Choices:
A. Grade 1
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 3
D. Grade 2


Question: Using the Fuhrman nuclear grading system, which grade should be assigned to this tumor?

Choices:
A. Grade 3
B. Grade 2
C. Grade 4
D. Grade 1


Question: What grade best represents this tumor under the FIGO histologic grading system?

Choices:
A. Grade 1
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 2
D. Grade 3


Question: What is the overall grade of the viable tumor under the Fuhrman nuclear grading system?

Choices:
A. Grade 2
B. Grade 1
C. Grade 3
D. Grade 4


Question: What is the overall degree of histologic differentiation in this tumor?

Choices:
A. Undifferentiated or anaplastic
B. Poorly differentiated
C. Moderately differentiated
D. Well differentiated


Question: Based on the applicable criteria, which grade under the FIGO histologic grading system is supported?

Choices:
A. Grade 3
B. Grade 2
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 1


Question: How differentiated is this tumor on H&E?

Choices:
A. Poorly differentiated
B. Undifferentiated or anaplastic
C. Well differentiated
D. Moderately differentiated


Question: What final differentiation category should be assigned to this tumor?

Choices:
A. Undifferentiated or anaplastic
B. Poorly differentiated
C. Well differentiated
D. Moderately differentiated


Question: What final grade under the Nottingham histologic grading system should be assigned to this tumor?

Choices:
A. Grade 2
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 1
D. Grade 3


Question: Which grading assessment is most appropriate under the Nottingham histologic grading system?

Choices:
A. Grade 3
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 2
D. Grade 1


Question: What final grade under the FIGO histologic grading system should be assigned to this tumor?

Choices:
A. Grade 1
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 3
D. Grade 2


Question: Which description best reflects the histologic differentiation of this tumor?

Choices:
A. Well differentiated
B. Poorly differentiated
C. Undifferentiated or anaplastic
D. Moderately differentiated


Question: What is the overall grade of the viable tumor under the FIGO histologic grading system?

Choices:
A. Grade 2
B. Grade 1
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 3


Question: How should this tumor be graded using the Nottingham histologic grading system?

Choices:
A. Grade 2
B. Grade 1
C. Cannot be reliably graded from the submitted H&E slides
D. Grade 3


Question: What is the overall grade of the viable tumor under the Nottingham histologic grading system?

Choices:
A. Grade 1
B. Grade 3
C. Grade 2
D. Cannot be reliably graded from the submitted H&E slides


Question: Which grade under the Fuhrman nuclear grading system is supported by the tumor morphology?

Choices:
A. Grade 2
B. Grade 4
C. Grade 3
D. Grade 1


Question: Which grade category under the FIGO histologic grading system best matches this tumor?

Choices:
A. Grade 3
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 2
D. Grade 1


Question: Which category best characterizes this tumor's degree of differentiation?

Choices:
A. Moderately differentiated
B. Well differentiated
C. Poorly differentiated
D. Undifferentiated or anaplastic


Question: What grade best represents this tumor under the Fuhrman nuclear grading system?

Choices:
A. Grade 3
B. Grade 2
C. Grade 4
D. Grade 1


Question: Which grading assessment is most appropriate under the Fuhrman nuclear grading system?

Choices:
A. Grade 3
B. Grade 4
C. Grade 1
D. Grade 2


Question: Based on the applicable criteria, which grade under the Fuhrman nuclear grading system is supported?

Choices:
A. Grade 4
B. Grade 3
C. Grade 1
D. Grade 2


Question: What degree of tumor differentiation should be recorded?

Choices:
A. Well differentiated
B. Undifferentiated or anaplastic
C. Poorly differentiated
D. Moderately differentiated


Question: How should this tumor's histologic differentiation be categorized?

Choices:
A. Moderately differentiated
B. Well differentiated
C. Undifferentiated or anaplastic
D. Poorly differentiated


Question: Which description best reflects the histologic differentiation of this tumor?

Choices:
A. Poorly differentiated
B. Moderately differentiated
C. Undifferentiated or anaplastic
D. Well differentiated


Question: What final differentiation category should be assigned to this tumor?

Choices:
A. Undifferentiated or anaplastic
B. Poorly differentiated
C. Moderately differentiated
D. Well differentiated


Question: Which grade under the Fuhrman nuclear grading system belongs in the final pathology assessment?

Choices:
A. Grade 2
B. Grade 3
C. Grade 1
D. Grade 4


Question: Which grade category under the Fuhrman nuclear grading system best matches this tumor?

Choices:
A. Grade 3
B. Grade 4
C. Grade 1
D. Grade 2


Question: What grade best represents this tumor under the Nottingham histologic grading system?

Choices:
A. Grade 2
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 1
D. Grade 3


Question: Which grade category under the FIGO histologic grading system best matches this tumor?

Choices:
A. Grade 2
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 1
D. Grade 3


Question: Which grading assessment is most appropriate under the Fuhrman nuclear grading system?

Choices:
A. Grade 1
B. Grade 4
C. Grade 3
D. Grade 2


Question: What degree of tumor differentiation should be recorded?

Choices:
A. Poorly differentiated
B. Moderately differentiated
C. Well differentiated
D. Undifferentiated or anaplastic


Question: What final differentiation category should be assigned to this tumor?

Choices:
A. Poorly differentiated
B. Moderately differentiated
C. Well differentiated
D. Undifferentiated or anaplastic


Question: Which differentiation category best matches the viable tumor?

Choices:
A. Poorly differentiated
B. Well differentiated
C. Undifferentiated or anaplastic
D. Moderately differentiated


Question: How should tumor differentiation appear in the final pathology assessment?

Choices:
A. Well differentiated
B. Moderately differentiated
C. Undifferentiated or anaplastic
D. Poorly differentiated


Question: What degree of tumor differentiation should be recorded?

Choices:
A. Well differentiated
B. Poorly differentiated
C. Moderately differentiated
D. Undifferentiated or anaplastic


Question: What is the overall grade of the viable tumor under the Fuhrman nuclear grading system?

Choices:
A. Grade 2
B. Grade 1
C. Grade 4
D. Grade 3


Question: Based on the applicable criteria, which grade under the Fuhrman nuclear grading system is supported?

Choices:
A. Grade 1
B. Grade 4
C. Grade 3
D. Grade 2


Question: How differentiated is this tumor on H&E?

Choices:
A. Well differentiated
B. Poorly differentiated
C. Moderately differentiated
D. Undifferentiated or anaplastic


Question: How should tumor differentiation appear in the final pathology assessment?

Choices:
A. Moderately differentiated
B. Poorly differentiated
C. Undifferentiated or anaplastic
D. Well differentiated


Question: What differentiation assessment is supported by the tumor morphology?

Choices:
A. Poorly differentiated
B. Undifferentiated or anaplastic
C. Moderately differentiated
D. Well differentiated


Question: Using the Fuhrman nuclear grading system, which grade should be assigned to this tumor?

Choices:
A. Grade 3
B. Grade 4
C. Grade 1
D. Grade 2


Question: What is the overall grade of the viable tumor under the FIGO histologic grading system?

Choices:
A. Grade 3
B. Grade 2
C. Grade 1
D. Cannot be reliably graded from the submitted H&E slides


Question: Which grade category under the Nottingham histologic grading system best matches this tumor?

Choices:
A. Grade 3
B. Cannot be reliably graded from the submitted H&E slides
C. Grade 1
D. Grade 2


Question: Which differentiation category should be entered in the pathology report?

Choices:
A. Undifferentiated or anaplastic
B. Well differentiated
C. Poorly differentiated
D. Moderately differentiated


Question: Which differentiation category should be entered in the pathology report?

Choices:
A. Undifferentiated or anaplastic
B. Poorly differentiated
C. Well differentiated
D. Moderately differentiated


Question: Which grading assessment is most appropriate under the FIGO histologic grading system?

Choices:
A. Grade 1
B. Grade 2
C. Grade 3
D. Cannot be reliably graded from the submitted H&E slides


Question: Which grade under the Fuhrman nuclear grading system is supported by the tumor morphology?

Choices:
A. Grade 1
B. Grade 4
C. Grade 3
D. Grade 2


Question: How should this tumor's histologic differentiation be categorized?

Choices:
A. Poorly differentiated
B. Well differentiated
C. Moderately differentiated
D. Undifferentiated or anaplastic


Question: What final differentiation category should be assigned to this tumor?

Choices:
A. Undifferentiated or anaplastic
B. Well differentiated
C. Moderately differentiated
D. Poorly differentiated


Question: What grade under the Fuhrman nuclear grading system should be entered in the pathology report?

Choices:
A. Grade 2
B. Grade 3
C. Grade 1
D. Grade 4


Question: Which differentiation category should be entered in the pathology report?

Choices:
A. Well differentiated
B. Moderately differentiated
C. Poorly differentiated
D. Undifferentiated or anaplastic


Question: What is the overall grade of the viable tumor under the FIGO histologic grading system?

Choices:
A. Cannot be reliably graded from the submitted H&E slides
B. Grade 1
C. Grade 2
D. Grade 3


Question: What grade best represents this tumor under the Fuhrman nuclear grading system?

Choices:
A. Grade 1
B. Grade 2
C. Grade 3
D. Grade 4


Question: What level of mitotic activity is present in the submitted tumor?

Choices:
A. High mitotic activity
B. Intermediate mitotic activity
C. Cannot be assessed from the available tumor
D. Absent or low mitotic activity


Question: How should mitotic activity be categorized after review of viable tumor?

Choices:
A. Cannot be assessed from the available tumor
B. Intermediate mitotic activity
C. Absent or low mitotic activity
D. High mitotic activity


Question: What level of mitotic activity is present in the submitted tumor?

Choices:
A. Cannot be assessed from the available tumor
B. Absent or low mitotic activity
C. High mitotic activity
D. Intermediate mitotic activity


Question: What level of mitotic activity is present in the submitted tumor?

Choices:
A. Cannot be assessed from the available tumor
B. Intermediate mitotic activity
C. Absent or low mitotic activity
D. High mitotic activity

Cannot be assessed from the available tumor


Question: What level of mitotic activity is present in the submitted tumor?

Choices:
A. Absent or low mitotic activity
B. Intermediate mitotic activity
C. Cannot be assessed from the available tumor
D. High mitotic activity


Question: What level of mitotic activity is present in the submitted tumor?

Choices:
A. Absent or low mitotic activity
B. Intermediate mitotic activity
C. High mitotic activity
D. Cannot be assessed from the available tumor


Question: What level of mitotic activity is present in the submitted tumor?

Choices:
A. Absent or low mitotic activity
B. Intermediate mitotic activity
C. Cannot be assessed from the available tumor
D. High mitotic activity

Cannot be assessed from the available tumor


Question: Which category best summarizes mitotic activity in the viable tumor?

Choices:
A. Intermediate mitotic activity
B. Absent or low mitotic activity
C. High mitotic activity
D. Cannot be assessed from the available tumor


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Both perineural and lymphovascular invasion
C. Lymphovascular invasion only
D. Perineural invasion only

Neither perineural nor lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Lymphovascular invasion only
B. Perineural invasion only
C. Both perineural and lymphovascular invasion
D. Neither perineural nor lymphovascular invasion

Both perineural and lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Lymphovascular invasion only
B. Both perineural and lymphovascular invasion
C. Perineural invasion only
D. Neither perineural nor lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Both perineural and lymphovascular invasion
C. Lymphovascular invasion only
D. Perineural invasion only


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Both perineural and lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Both perineural and lymphovascular invasion
B. Neither perineural nor lymphovascular invasion
C. Perineural invasion only
D. Lymphovascular invasion only


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Lymphovascular invasion only
C. Both perineural and lymphovascular invasion
D. Perineural invasion only


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Lymphovascular invasion only
B. Both perineural and lymphovascular invasion
C. Neither perineural nor lymphovascular invasion
D. Perineural invasion only

Both perineural and lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Both perineural and lymphovascular invasion
C. Perineural invasion only
D. Lymphovascular invasion only

Both perineural and lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Perineural invasion only
B. Both perineural and lymphovascular invasion
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Lymphovascular invasion only
B. Both perineural and lymphovascular invasion
C. Neither perineural nor lymphovascular invasion
D. Perineural invasion only

Both perineural and lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Perineural invasion only
B. Both perineural and lymphovascular invasion
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Both perineural and lymphovascular invasion
B. Neither perineural nor lymphovascular invasion
C. Perineural invasion only
D. Lymphovascular invasion only


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Lymphovascular invasion only
C. Both perineural and lymphovascular invasion
D. Perineural invasion only


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Both perineural and lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Both perineural and lymphovascular invasion
B. Lymphovascular invasion only
C. Perineural invasion only
D. Neither perineural nor lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Lymphovascular invasion only
B. Neither perineural nor lymphovascular invasion
C. Both perineural and lymphovascular invasion
D. Perineural invasion only

Neither perineural nor lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Perineural invasion only
C. Both perineural and lymphovascular invasion
D. Lymphovascular invasion only

Both perineural and lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Both perineural and lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Both perineural and lymphovascular invasion
C. Perineural invasion only
D. Lymphovascular invasion only

Neither perineural nor lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Lymphovascular invasion only
B. Perineural invasion only
C. Both perineural and lymphovascular invasion
D. Neither perineural nor lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Both perineural and lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Both perineural and lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Lymphovascular invasion only
C. Both perineural and lymphovascular invasion
D. Perineural invasion only


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Perineural invasion only
B. Both perineural and lymphovascular invasion
C. Neither perineural nor lymphovascular invasion
D. Lymphovascular invasion only

Neither perineural nor lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Perineural invasion only
B. Neither perineural nor lymphovascular invasion
C. Both perineural and lymphovascular invasion
D. Lymphovascular invasion only

Neither perineural nor lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Lymphovascular invasion only
C. Both perineural and lymphovascular invasion
D. Perineural invasion only


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Both perineural and lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Lymphovascular invasion only
B. Neither perineural nor lymphovascular invasion
C. Both perineural and lymphovascular invasion
D. Perineural invasion only


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Perineural invasion only
B. Neither perineural nor lymphovascular invasion
C. Both perineural and lymphovascular invasion
D. Lymphovascular invasion only

Neither perineural nor lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Perineural invasion only
C. Both perineural and lymphovascular invasion
D. Lymphovascular invasion only

Both perineural and lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Both perineural and lymphovascular invasion
B. Neither perineural nor lymphovascular invasion
C. Lymphovascular invasion only
D. Perineural invasion only


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Perineural invasion only
B. Both perineural and lymphovascular invasion
C. Neither perineural nor lymphovascular invasion
D. Lymphovascular invasion only


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Lymphovascular invasion only
C. Perineural invasion only
D. Both perineural and lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Both perineural and lymphovascular invasion
B. Lymphovascular invasion only
C. Perineural invasion only
D. Neither perineural nor lymphovascular invasion

Both perineural and lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Perineural invasion only
B. Lymphovascular invasion only
C. Neither perineural nor lymphovascular invasion
D. Both perineural and lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Both perineural and lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Both perineural and lymphovascular invasion
B. Perineural invasion only
C. Neither perineural nor lymphovascular invasion
D. Lymphovascular invasion only

Both perineural and lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Lymphovascular invasion only
B. Both perineural and lymphovascular invasion
C. Perineural invasion only
D. Neither perineural nor lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Both perineural and lymphovascular invasion
B. Neither perineural nor lymphovascular invasion
C. Perineural invasion only
D. Lymphovascular invasion only


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Lymphovascular invasion only
B. Both perineural and lymphovascular invasion
C. Perineural invasion only
D. Neither perineural nor lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Lymphovascular invasion only
B. Neither perineural nor lymphovascular invasion
C. Both perineural and lymphovascular invasion
D. Perineural invasion only


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Perineural invasion only
B. Neither perineural nor lymphovascular invasion
C. Both perineural and lymphovascular invasion
D. Lymphovascular invasion only


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Lymphovascular invasion only
B. Perineural invasion only
C. Both perineural and lymphovascular invasion
D. Neither perineural nor lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Perineural invasion only
C. Both perineural and lymphovascular invasion
D. Lymphovascular invasion only

Neither perineural nor lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Lymphovascular invasion only
C. Perineural invasion only
D. Both perineural and lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Both perineural and lymphovascular invasion
B. Neither perineural nor lymphovascular invasion
C. Lymphovascular invasion only
D. Perineural invasion only


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Perineural invasion only
B. Lymphovascular invasion only
C. Both perineural and lymphovascular invasion
D. Neither perineural nor lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Both perineural and lymphovascular invasion
B. Neither perineural nor lymphovascular invasion
C. Perineural invasion only
D. Lymphovascular invasion only


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Perineural invasion only
B. Lymphovascular invasion only
C. Neither perineural nor lymphovascular invasion
D. Both perineural and lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Lymphovascular invasion only
B. Neither perineural nor lymphovascular invasion
C. Perineural invasion only
D. Both perineural and lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Lymphovascular invasion only
B. Perineural invasion only
C. Neither perineural nor lymphovascular invasion
D. Both perineural and lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Both perineural and lymphovascular invasion

Both perineural and lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Both perineural and lymphovascular invasion

Both perineural and lymphovascular invasion


Question: Which combination of perineural and lymphovascular invasion is identified in the submitted tumor sections?

Choices:
A. Perineural invasion only
B. Lymphovascular invasion only
C. Neither perineural nor lymphovascular invasion
D. Both perineural and lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Perineural invasion only
B. Lymphovascular invasion only
C. Neither perineural nor lymphovascular invasion
D. Both perineural and lymphovascular invasion


Question: After microscopic review of all submitted H&E slides, which focal route-of-spread pattern is present?

Choices:
A. Both perineural and lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion

Both perineural and lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Perineural invasion only
B. Both perineural and lymphovascular invasion
C. Lymphovascular invasion only
D. Neither perineural nor lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Lymphovascular invasion only
C. Perineural invasion only
D. Both perineural and lymphovascular invasion

Both perineural and lymphovascular invasion


Question: Which focal invasion pattern is supported by review of the submitted H&E material?

Choices:
A. Neither perineural nor lymphovascular invasion
B. Perineural invasion only
C. Lymphovascular invasion only
D. Both perineural and lymphovascular invasion

Neither perineural nor lymphovascular invasion


Question: What combination of microscopic perineural and lymphovascular spread should be recorded for this case?

Choices:
A. Perineural invasion only
B. Neither perineural nor lymphovascular invasion
C. Both perineural and lymphovascular invasion
D. Lymphovascular invasion only

Neither perineural nor lymphovascular invasion


Question: How should tumor capsular invasion be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: Which assessment of visceral pleural invasion is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Suspicious but not definitive
C. Not identified after adequate review
D. Cannot be assessed in the submitted material


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Definitely identified
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Not identified after adequate review
D. Definitely identified


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Not identified after adequate review
D. Cannot be assessed in the submitted material


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Suspicious but not definitive
D. Cannot be assessed in the submitted material


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Definitely identified
D. Not identified after adequate review


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Definitely identified
D. Suspicious but not definitive


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Suspicious but not definitive
B. Cannot be assessed in the submitted material
C. Definitely identified
D. Not identified after adequate review


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Suspicious but not definitive


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: Which assessment of visceral pleural invasion is supported by the available tumor sections?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Suspicious but not definitive
D. Cannot be assessed in the submitted material


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Not identified after adequate review


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Definitely identified
C. Suspicious but not definitive
D. Not identified after adequate review


Question: Is visceral pleural invasion identified in the submitted H&E sections?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Suspicious but not definitive


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Definitely identified
D. Suspicious but not definitive


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Not identified after adequate review
D. Cannot be assessed in the submitted material


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Suspicious but not definitive
D. Definitely identified


Question: Which assessment of visceral pleural invasion is supported by the available tumor sections?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Not identified after adequate review
D. Cannot be assessed in the submitted material


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Definitely identified
D. Not identified after adequate review


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Definitely identified
C. Suspicious but not definitive
D. Not identified after adequate review


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Suspicious but not definitive
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Definitely identified


Question: Is visceral pleural invasion identified in the submitted H&E sections?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: How should tumor capsular invasion be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Cannot be assessed in the submitted material
B. Definitely identified
C. Not identified after adequate review
D. Suspicious but not definitive


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Suspicious but not definitive
D. Definitely identified


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Suspicious but not definitive


Question: How should tumor capsular invasion be recorded after review of the submitted material?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: How should tumor capsular invasion be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Suspicious but not definitive
D. Definitely identified


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Cannot be assessed in the submitted material
B. Definitely identified
C. Suspicious but not definitive
D. Not identified after adequate review


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Not identified after adequate review
D. Definitely identified


Question: Is visceral pleural invasion identified in the submitted H&E sections?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Not identified after adequate review
D. Definitely identified


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Suspicious but not definitive
D. Cannot be assessed in the submitted material


Question: Is visceral pleural invasion identified in the submitted H&E sections?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Not identified after adequate review
D. Definitely identified


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: Is visceral pleural invasion identified in the submitted H&E sections?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Not identified after adequate review


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Suspicious but not definitive
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Definitely identified


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Definitely identified
D. Suspicious but not definitive


Question: How should tumor capsular invasion be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: How should tumor capsular invasion be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Not identified after adequate review


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Not identified after adequate review


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Definitely identified


Question: Is extranodal extension identified in the submitted H&E sections?

Choices:
A. Suspicious but not definitive
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Cannot be assessed in the submitted material
B. Definitely identified
C. Suspicious but not definitive
D. Not identified after adequate review


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Definitely identified


Question: How should tumor capsular invasion be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Definitely identified
D. Suspicious but not definitive


Question: Which assessment of visceral pleural invasion is supported by the available tumor sections?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Definitely identified
D. Not identified after adequate review


Question: Is visceral pleural invasion identified in the submitted H&E sections?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Not identified after adequate review
D. Definitely identified


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Suspicious but not definitive
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Definitely identified


Question: Which assessment of visceral pleural invasion is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Suspicious but not definitive
C. Cannot be assessed in the submitted material
D. Not identified after adequate review


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Definitely identified
D. Suspicious but not definitive


Question: How should tumor capsular invasion be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Definitely identified
D. Suspicious but not definitive


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Cannot be assessed in the submitted material
B. Suspicious but not definitive
C. Not identified after adequate review
D. Definitely identified


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Suspicious but not definitive
B. Cannot be assessed in the submitted material
C. Definitely identified
D. Not identified after adequate review


Question: Is visceral pleural invasion identified in the submitted H&E sections?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Suspicious but not definitive


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Suspicious but not definitive
D. Definitely identified


Question: Is visceral pleural invasion identified in the submitted H&E sections?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Suspicious but not definitive
D. Definitely identified


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Definitely identified
D. Suspicious but not definitive


Question: Which assessment of extranodal extension is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Suspicious but not definitive


Question: How should visceral pleural invasion be recorded after review of the submitted material?

Choices:
A. Not identified after adequate review
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Definitely identified


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Not identified after adequate review
D. Suspicious but not definitive


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Cannot be assessed in the submitted material
B. Not identified after adequate review
C. Definitely identified
D. Suspicious but not definitive


Question: Which assessment of visceral pleural invasion is supported by the available tumor sections?

Choices:
A. Not identified after adequate review
B. Suspicious but not definitive
C. Definitely identified
D. Cannot be assessed in the submitted material


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Definitely identified
B. Suspicious but not definitive
C. Not identified after adequate review
D. Cannot be assessed in the submitted material


Question: Is tumor capsular invasion identified in the submitted H&E sections?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Suspicious but not definitive
D. Cannot be assessed in the submitted material


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Not identified after adequate review
B. Definitely identified
C. Suspicious but not definitive
D. Cannot be assessed in the submitted material


Question: Which assessment of tumor capsular invasion is supported by the available tumor sections?

Choices:
A. Suspicious but not definitive
B. Not identified after adequate review
C. Cannot be assessed in the submitted material
D. Definitely identified


Question: How should extranodal extension be recorded after review of the submitted material?

Choices:
A. Definitely identified
B. Cannot be assessed in the submitted material
C. Suspicious but not definitive
D. Not identified after adequate review


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. Isolated tumor cells or micrometastasis only
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. At least one macrometastasis


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. Isolated tumor cells or micrometastasis only


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative

Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative

Cannot be assessed from the submitted specimen


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: How should local extension of this renal tumor be categorized morphologically?

Choices:
A. Confined to the kidney
B. Invades a major renal vein branch or the vena cava
C. Invades perinephric or renal sinus soft tissue
D. Extends beyond Gerota fascia or directly invades an adjacent organ


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. At least one macrometastasis


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. At least one macrometastasis


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: Which anatomic level of invasion is reached by this renal tumor?

Choices:
A. Confined to the kidney
B. Invades perinephric or renal sinus soft tissue
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified

Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Negative with a clear margin
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative


Question: What deepest anatomic extent should be documented for this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Invades a major renal vein branch or the vena cava
C. Confined to the kidney
D. Extends beyond Gerota fascia or directly invades an adjacent organ


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only

Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What is the greatest anatomic extent of invasion by this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Confined to the kidney
C. Extends beyond Gerota fascia or directly invades an adjacent organ
D. Invades a major renal vein branch or the vena cava


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. No metastatic tumor identified


Question: What is the deepest local extension of this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Extends beyond Gerota fascia or directly invades an adjacent organ
C. Invades a major renal vein branch or the vena cava
D. Confined to the kidney

Invades perinephric or renal sinus soft tissue


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: How should the maximum regional nodal tumor-burden category be documented?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: Which overall regional nodal tumor-burden category is supported by the submitted material?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only

Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Negative with a clear margin
D. Close but negative


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified

Cannot be assessed from the submitted specimen


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. Isolated tumor cells or micrometastasis only
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. Cannot be assessed from the submitted specimen
D. At least one macrometastasis


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: Which level of local invasion is supported by the submitted sections of this renal tumor?

Choices:
A. Invades perinephric or renal sinus soft tissue
B. Invades a major renal vein branch or the vena cava
C. Confined to the kidney
D. Extends beyond Gerota fascia or directly invades an adjacent organ


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Close but negative
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Close but negative
D. Positive for invasive tumor


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: How should regional nodal tumor burden be categorized?

Choices:
A. Cannot be assessed from the submitted specimen
B. No metastatic tumor identified
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. No metastatic tumor identified
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. No metastatic tumor identified


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. At least one macrometastasis
B. No metastatic tumor identified
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Positive for invasive tumor


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: Which level of local invasion is supported by the submitted sections of this endometrial tumor?

Choices:
A. Myometrial invasion involving less than half of its thickness
B. Myometrial invasion involving at least half of its thickness
C. No myometrial invasion
D. Cervical stromal, serosal, adnexal, or adjacent-organ extension

Cervical stromal, serosal, adnexal, or adjacent-organ extension


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Negative with a clear margin
B. Positive for invasive tumor
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Negative with a clear margin
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Close but negative


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. Isolated tumor cells or micrometastasis only


Question: What local anatomic extent is supported for this renal tumor?

Choices:
A. Confined to the kidney
B. Extends beyond Gerota fascia or directly invades an adjacent organ
C. Invades perinephric or renal sinus soft tissue
D. Invades a major renal vein branch or the vena cava

Invades perinephric or renal sinus soft tissue


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Close but negative
D. Cannot be assessed from the submitted specimen


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. Isolated tumor cells or micrometastasis only
B. No metastatic tumor identified
C. At least one macrometastasis
D. Cannot be assessed from the submitted specimen


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: What is the greatest anatomic extent of invasion supported for this colorectal tumor?

Choices:
A. Reaches the serosal surface or directly invades an adjacent organ
B. Limited to the submucosa
C. Extends through muscularis propria into pericolorectal tissue
D. Invades the muscularis propria

Extends through muscularis propria into pericolorectal tissue


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: What level of nodal metastatic burden is supported by the submitted H&E material?

Choices:
A. No metastatic tumor identified
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. Isolated tumor cells or micrometastasis only


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Close but negative


Question: How should the invasive-tumor margin assessment appear in the final report?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: Based on the submitted material, what is the greatest regional nodal tumor burden that can be assessed?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. At least one macrometastasis
D. No metastatic tumor identified


Question: How should invasive-tumor margin status be recorded?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen

Cannot be assessed from the submitted specimen


Question: Which category best summarizes tumor involvement of the regional lymph nodes?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Close but negative


Question: What is the greatest nodal tumor burden, if any, identified in the submitted material?

Choices:
A. Cannot be assessed from the submitted specimen
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. No metastatic tumor identified


Question: What local anatomic extent is supported for this colorectal tumor?

Choices:
A. Invades the muscularis propria
B. Extends through muscularis propria into pericolorectal tissue
C. Reaches the serosal surface or directly invades an adjacent organ
D. Limited to the submucosa

Extends through muscularis propria into pericolorectal tissue


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. At least one macrometastasis


Question: What level of nodal metastatic burden is supported by the submitted H&E material?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Close but negative


Question: Which nodal tumor-burden category should be entered for this case?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Isolated tumor cells or micrometastasis only
D. Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What is the largest metastatic deposit category, if any, supported by the submitted material?

Choices:
A. At least one macrometastasis
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. Cannot be assessed from the submitted specimen


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Cannot be assessed from the submitted specimen
B. Negative with a clear margin
C. Positive for invasive tumor
D. Close but negative


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What margin assessment is supported for invasive tumor in this specimen?

Choices:
A. Positive for invasive tumor
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Negative with a clear margin


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What is the status of the submitted margins with respect to invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Close but negative


Question: Which description best reflects the status of the submitted resection margins for invasive tumor?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. Cannot be assessed from the submitted specimen
B. Isolated tumor cells or micrometastasis only
C. No metastatic tumor identified
D. At least one macrometastasis

Cannot be assessed from the submitted specimen


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Close but negative
B. Positive for invasive tumor
C. Negative with a clear margin
D. Cannot be assessed from the submitted specimen


Question: How should the closest relevant margin be reported in relation to invasive tumor?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Positive for invasive tumor
D. Cannot be assessed from the submitted specimen


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Cannot be assessed from the submitted specimen
B. Positive for invasive tumor
C. Close but negative
D. Negative with a clear margin


Question: Which finding best summarizes involvement of the regional lymph nodes?

Choices:
A. At least one macrometastasis
B. Cannot be assessed from the submitted specimen
C. No metastatic tumor identified
D. Isolated tumor cells or micrometastasis only


Question: What should be communicated about the closest relevant margin for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Negative with a clear margin
D. Positive for invasive tumor


Question: What final margin category should be entered for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin

Cannot be assessed from the submitted specimen


Question: What margin status is supported for invasive tumor in the submitted specimen?

Choices:
A. Close but negative
B. Negative with a clear margin
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: How should regional nodal tumor burden be categorized?

Choices:
A. No metastatic tumor identified
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. Isolated tumor cells or micrometastasis only


Question: Considering all relevant margins, which margin-status category is most adverse for invasive tumor?

Choices:
A. Positive for invasive tumor
B. Cannot be assessed from the submitted specimen
C. Close but negative
D. Negative with a clear margin


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Close but negative
B. Cannot be assessed from the submitted specimen
C. Positive for invasive tumor
D. Negative with a clear margin


Question: What is the most adverse invasive-tumor margin status in the submitted specimen?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor


Question: What final margin status should be assigned for invasive tumor?

Choices:
A. Negative with a clear margin
B. Close but negative
C. Cannot be assessed from the submitted specimen
D. Positive for invasive tumor

Cannot be assessed from the submitted specimen


Question: What final nodal tumor-burden category should be assigned?

Choices:
A. Isolated tumor cells or micrometastasis only
B. At least one macrometastasis
C. Cannot be assessed from the submitted specimen
D. No metastatic tumor identified


Question: Which nodal involvement category is supported by the examined sections?

Choices:
A. Isolated tumor cells or micrometastasis only
B. Cannot be assessed from the submitted specimen
C. At least one macrometastasis
D. No metastatic tumor identified